Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
It provides background insulin coverage and is not a rapid-acting mealtime insulin or a treatment for diabetic ketoacidosis
Phase 3 results pushed even further, with the TRIUMPH-4 trial reporting 28.7% mean weight loss at 12mg
Pregnant or breastfeeding individuals should consult a healthcare professional
They block gastric emptying, decrease appetite, and reduces weight, which makes them particularly profitable in type 2 diabetic patients and obese patients
At ~5382 Da, FOXO4-DRI is above the typical renal filtration threshold (~60 kDa for globular proteins, but much lower for linear peptides), suggesting renal clearance may contribute to elimination
US$ 24.91
US$ 25.85
US$ 28.04
